Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Centre National De La Recherche Scientifique

Universitë De Bordeaux

Etat Francais Represente Par Le Delegue General Pour L'armement

Lfb Biotechnologies

Centre National De La Recherche Scientifique-cnrs

Université Grenoble I Joseph Fourier

Alexandre Fontayne

Christophe De Romeuf

Philippe Mondon

Francois Coutard

Abdessatar Chtourou

Sylvie Jorieux

Khalil Bouayadi

Abdelhakim Kharrat

Philippe Thullier

Celine Monnet-Mars

Nathalie Fournier

Jean-Luc Plantier

Cyril Lorenzato

Gisèle Clofent-Sanchez

Benoit Polack

Céline Monnet

Céline Monnet-Mars

Jeanny Laroche-Traineau

Aline Thomas

Audrey Hémadou

Martine Cérutti

Marie-Josée Jacobin-Valat

Marie-Claire Dagher

Raphaël Marlu

Toufik Abache

François Coutard

The present invention relates to the use of antibody Fc fragments in the treatment of autoimmune and/or inflammatory diseases, said Fc fragments being isolated recombinant Fc fragments having a modified affinity for at least one of the Fc receptors (FcR), particularly an increased affinity to FcRn.

Use of modified Fc fragments in immunotherapy

Disclosed is to a polypeptide including a mutated Fc region and having functional activity, mediated by the Fc region, that is modified compared with that of a parent polypeptide. The Fc region includes at least one combination of 2 mutations, the combination being selected from among one mutation selected from among a first set of mutations, and at least one mutation selected from among a second set of mutations, and provided that mutation (i) does not take place on the same amino acid as mutation (ii). Also disclosed are use of the polypeptide, compositions including the same, and methods for preparing the polypeptide.

Fc mutants with modified functional activity

A specific binding molecule is provided which binds to galectin-3 protein, methods of their production and methods of use.

Specific binding molecule directed against galectin-3 protein

The invention relates to chimeric or humanised anti-CD303 antibodies to nucleic acids coding for the heavy and light chains of these antibodies, expression vectors, host cells, transgenic non-human animals or transgenic plants expressing said antibodies, as well as to the uses thereof in the treatment or prevention of blastic plasmacytoid dendritic cell neoplasms (BPDCN) or inflammatory diseases, in particular autoimmune diseases, involving plasmacytoid dendritic cells.

Anti-CD303 monoclonal antibodies

A transcription unit constituted by a polynucleotide including the hCMVie virus enhancer, the enhancer having the nucleotide sequence SEQ ID NO: 1, or a nucleotide acid having at least 70% sequence identity with the sequence SEQ ID NO: 1 and essentially having transcription activation properties, and the promoter region of Cyclin-Dependent Kinase 9 (CDK9), the promoter region having the nucleotide sequence SEQ ID NO: 2, or a nucleotide acid having at least 70% sequence identity with the sequence SEQ ID NO: 2 and essentially having a promoter activity.

Transcription unit and use thereof in expression vectors

Novel transcription units that may be used in expression vectors. The transcription unit allow antibodies to be produced whose gain in productivity is not linked to a particular antigenic target antibody and therefore by extrapolation to a given recombinant protein, nor linked to the culture medium.

Transcription units and the use thereof in expression vectors

A use of a signal peptide for producing a recombinant polypeptide of interest in an expression system, the signal peptide includes at least 12 amino acids of formula (I):(X1)X2X3X4SX5X6X7,wherein:

Signal peptide, and use thereof for producing recombinant proteins

A chimeric monoclonal antibody targeted at ricin, in which the light chain and heavy chain are such that:

Chimeric anti-ricin antibody

Growing community of inventors

La Madeleine, France

Alexandre Fontayne